ITCI - Intra-Cellular Therapies GAAP EPS of -$0.46 beats by $0.16 revenue of $95.31M beats by $2.9M

2023-05-04 07:37:59 ET

• Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q1 GAAP EPS of -$0.46 beats by $0.16 .
• Revenue of $95.31M (+172.3% Y/Y) beats by $2.9M .
• CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase
• Q1 2023 CAPLYTA total prescriptions increased 159%, versus the same period in 2022 and 16% sequentially versus Q4 2022
• Reiterating CAPLYTA 2023 net product sales guidance of $430 to $455 million

For further details see: